New weapon tested against deadly brain cancers that Won't quit
NCT ID NCT07455045
Summary
This is an early-stage study to test the safety and find the right dose of a new drug called FZ-AD005 for adults with aggressive brain tumors that have come back or stopped responding to standard treatments. The study will enroll about 40 people with high-grade gliomas, including glioblastoma and diffuse midline glioma. Researchers will closely monitor how the body handles the drug and look for any early signs that it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.